((自动化翻译由路透提供，请见免责声明 ))
10月30日 - ** 远程医疗公司Hims & Hers Health 股价下跌16.05%，至18.67美元 ** 诺和诺德 减肥药Wegovy的最低剂量在美国FDA网站 (link)。
** FDA网站现在显示Wegovy的所有五种剂量强度和Ozempic的所有三种剂量强度均已上市
** Leerink Partners 表示："尽管 GLP-1 营收在公司总营收中仍占很小一部分，但 HIMS 的股价似乎因 GLP-1 的头条新闻而起伏不定。
** 我们认为，这种头条新闻压力的风险，以及反向波动的能力(，如上次 FDA 对短缺的澄清)，将继续推动 HIMS 股价出现不必要的波动，"券商补充道。
** 包括本交易日的走势在内，HIMS 的股价在今年已经上涨了一倍多。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.